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ABSTRACT
Background Treatment- related toxicity and delays in the 
management of this toxicity can impact the outcomes of 
patient with cancer. In Scotland, a national cancer helpline 
was established to provide triage assessment for patients 
receiving systemic anticancer therapy (SACT) in an 
attempt to minimise delays in toxicity management. In this 
article, we describe the use and impact of the helpline in 
our region over the last 5 years.
Methods Patients who contacted the NHS Tayside cancer 
helpline between 1 January 2016 and 31 December 2020 
were retrospectively identified. Patient demographics as 
well as the reason and outcome of each call was recorded. 
A descriptive analysis was performed.
Results 6562 individual patients received SACT and 
8385 calls were recorded during the time period. Median 
age of callers was 63 years (range 17–98) and 59.2% 
were women. Use of the helpline increased by 83.6% 
between 2016 and 2020, driven by an increase in in- 
hours calls. 41% of calls required review by a healthcare 
professional only, 24% required review and admission and 
the remaining 35% telephone advice only. The majority 
of cases (85%) were either assessed or advised solely 
by oncology. The proportional use of general practitioner 
services has decreased.
Conclusions The helpline provides a way for patients 
to report symptoms directly to their clinical team and 
receive appropriate specialist advice at an early stage. 
We demonstrate that most of these calls can be managed 
solely by our oncology team. This system can reduce 
pressure on other parts of the local health system.
INTRODUCTION
The global cancer burden is increasing annu-
ally. By 2030 it is predicted that there will 
be 4 million people in the United Kingdom 
(UK) living with cancer.1 Despite advances in 
cancer management, patients still experience 
a range of short and long- term treatment- 
related side effects, which can result in signif-
icant morbidity and mortality.2
In the UK, patients with cancer presenting 
to their local hospital as an emergency were 
historically admitted under general medical 
or internal medicine teams. This was despite 
a lack of experience in managing cancer 
treatment- related toxicity and the limited 
presence of specialist oncology support in 
smaller hospitals. In 2008, the National Confi-
dential Enquiry into Patient Outcome and 
Death (NCEPOD)3 found deficiencies in the 
management of patients with cancer admitted 
to hospital as an emergency; 49% of patients 
were deemed to have had less than optimal 
care and 27% of deaths were adjudged to 
have been hastened or caused by systemic 
anticancer therapy (SACT). The report high-
lighted contributing factors relating to both 
the communication and organisation of 
emergency care.
As a result, the National Chemotherapy 
Advisory Group was established.4 They 
proposed that each hospital with an emer-
gency department (ED) should have an 
acute oncology service (AOS) with the goal 
of approaching emergency cancer presenta-
tions in a more systematic way. The primary 
purpose of an AOS is to coordinate the 
management of patients who fall into one of 
three categories: those with cancer- related 
symptoms, those with cancer treatment 
toxicity, those requiring investigation and 
diagnosis of a new undiagnosed cancer.
In Scotland, in response to the NCEPOD 
report, a Short Life Working Group was estab-
lished and developed a dedicated 24- hour 
Cancer Treatment Helpline (CTH) which 
made use of the pre- existing NHS24 help-
line. At the time, it was the only validated 
service in the UK which utilised competently 
trained non- clinical staff to triage patients. 
The availability of the triage service provided 
a way for patients to directly report treatment- 
related toxicity and receive specialist input in 
a timely manner. This is important as delays 
in managing symptoms can impact patient 
outcomes—the best example of this is neutro-
penic sepsis.5
NHS Tayside is in the North- East of Scot-
land and serves a population of over 400 000 
people. The chemotherapy service and 
oncology department work across two main 
hospital sites; Ninewells Hospital in Dundee 
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geography of the region, patients can travel up to an hour 
for treatment. In January 2013, NHS Tayside established a 
triage service with the goal to enhance patient safety and 
outcomes for those receiving SACT who developed symp-
toms related to their treatment. This service was based in 
Dundee and was designed to provide triage assessment 
for all patients with cancer in the region through an initial 
telephone consultation, with the goal of streamlining the 
patient pathway.
In October 2015, NHS Tayside adopted the CTH, a 
national cancer helpline established in conjuncture with 
NHS Scotland and NHS24. In Tayside, unwell patients 
contacting the helpline in hours (weekdays between 08:00 
and 17:00), are directed to their local oncology service, 
where they are triaged by a trained oncology nurse. Those 
presenting out of hours (OOH) are initially diverted to 
the CTH for triage. During the initial OOH CTH tele-
phone triage assessment, a trained non- clinical handler 
triages callers using a series of questions from the United 
Kingdom Oncology Nursing Society (UKONS) toolkit.6 
This toolkit uses a structured method to communicate 
critical information required to assess and appropriate 
action.7 Symptoms are systematically scored according to 
colour; green (no or mild symptoms), amber (moderate 
symptoms) or red (severe symptoms).
Based on the triage outcome, the patient can either be 
managed over the phone, reviewed OOH in the patient’s 
local oncology department, seen by a general practitioner 
(GP) in the community or referred to their local acci-
dent and emergency department (ED). Each OOH call is 
communicated to the local oncology team the following 
day regardless of the outcome. Figure 1 provides an 
example of this patient pathway.
In this article, we provide a descriptive analysis of the 
use of the CTH in NHS Tayside over a 5- year period (1 
January 2016−31 December 2020) and discuss the impact 
it has had on the wider NHS in our region.
METHODS
Patients
Patients who contacted the NHS Tayside CTH between 1 
January 2016 and 31 December 2020 were retrospectively 
identified from existing paper call logs.
The date, time and outcome of each call were recorded 
along with the primary reason for the call. The reason 
for the call and the symptoms experienced by the patient 
were graded according to the UKONS triage tool.6 The 
time of the call was recorded as in hours (08:00–17:00 
on Monday to Friday) or OOH (17:00–08:00 on Monday–
Friday and all- day Saturday and Sunday). The outcome 
of the call was recorded as advice given, oncology review, 
NHS24 contact, paramedic/ED attendance or GP review. 
If the outcome resulted in a hospital admission, this was 
also recorded.
Electronic records were reviewed to complete data 
collection including confirmation of patient age, type 
of malignancy and SACT being received at the time of 
call. Treatment was classified as either chemotherapy, 
immunotherapy, tyrosine kinase inhibitors, combination 
therapy or other therapy. Combination therapy included 
combinations of same or different class drugs. Other 
therapy included radiotherapy (alone or in combina-
tion with chemotherapy), anti- oestrogen (exemestane, 
fulvestrant), CDK4/6 inhibitors (ribociclib, abemaci-
clib, palbociclib), PARP inhibitors (olaparib, niraparib), 
bisphosponates (pamidronate, zolendronic acid), 
targeted therapy (trastuzumab, pertuzumab, cetuximab, 
trastuzumab emtansine, bevacizumab, panitumumab, 
olaratumab), antiandrogens (enzalutamide, abiraterone), 
mTOR inhibitor (everolimus), somatostatin analogues 
(lanreotide) and dexamethasone. Accurate treatment 
data were unavailable for 2016 as it was not recorded on 
the paper logs at that stage.
All patient data were anonymised and collected in a 
password protected database on secure NHS computers.
Statistics
A descriptive analysis of patient demographics, the 
number of calls and the outcomes of each call was 
performed to assess differences between 2016 and 2020. 
Comparison of age of caller was compared between years 
using a two- sided unpaired t- test using Microsoft Excel.
Patient and public involvement
Patients were not involved in this retrospective study.
RESULTS
The total number of calls to the CTH between 1 January 
2016 and 31 December 2020 was 8385. The median age 
of callers was 63 (range 17–98) and 59.2% were women. 
From the data, we observed that 5466 (65.2%) of calls 
required the patient to be reviewed in person, while 
2919 (34.8%) received advice only. During the same time 
period 6562 individual patients received SACT in Tayside 
(table 1).
Figure 1 The CTH patient pathway in hours and out of 
hours in NHS Tayside. CTH, Cancer Treatment Helpline; 
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Use of CTH
The total number of calls to the CTH has gradually 
increased year on year, with an increase of 83.6% since 
2016 (table 1). Over the same time period, the number 
of patients being treated has increased by 15.4%. The 
number of in- hours calls to the CTH has also increased 
year on year from 530 in 2016 to 1421 in 2020, which 
corresponds to an increase in the proportion of calls. 
In the same time period, the number of OOH calls has 
remained relatively constant (table 2).
Analysing the data according to the day of the week, the 
highest number of calls were observed on a Monday, with 
a total of 1903 calls (20%) being logged. There was an 
annual increase in calls on each weekday while number 
of calls on weekends remained similar. The majority of 
calls during the day were received in the morning with 
the greatest number of Monday morning.
Use of CTH according the age
The median age of patients using the CTH was 63 years 
(range 17–98). There was an increase in the number of 
calls across all age groups from 2016 to 2020. There was 
no significant difference in median age of patient across 
the years (table 3).
Impact of tumour group and regime
In keeping with the incidence of the common cancers, 
the use of the CTH was greatest in patients with breast, 
lung and colorectal cancer (table 4). Most tumour groups 
had an increase in call number—the exception was pros-
tate cancer.
The greatest number of patients were on a form of 
combination treatment at the time of their call. Between 
2017 and 2020, the largest increase in use of the CTH 
was seen for immunotherapy and other treatments; 
215% and 225% increase, respectively. Calls related to 
chemotherapy, tyrosine kinase inhibitor and combination 
therapy increased by 21%, 41% and 26%, respectively.
Call outcome
Of the 8385 patients that have used the CTH between 
2016 and 2020—41% required review by a healthcare 
professional only, 24% required review and admission 
and the remaining 35% were given telephone advice only 
(table 5). The majority of cases (85%) were either assessed 
or advised solely by oncology. Of note, the proportional 
use of GP services has decreased, while the number of 
patients being reviewed by oncology has increased by an 
equal proportion. It is important to note the likely impact 
of the COVID-19 pandemic on the 2020 data, with an 
increase in advice and a fall in clinical review.
When assessed according to time of call, a difference in 
both type of outcome (table 6) and the admission rate is 
observed (table 7). Calls in hours had a higher review and 
discharge rate (30.1% vs 20.8%) and a lower admission 
rate (18.0% vs 33.6%) compared with OOH calls. We also 
observe that the admission rate in hours has reduced over 
time, while the OOH rate has remained stable (table 7).
DISCUSSION
The NCEPOD report in 2008 suggested that failure to 
provide a robust 24- hour oncology advice service resulted 
in compromised safety for patients with cancer.3 In 
response, Scotland established a 24- hour CTH with the 
aim of providing a direct route of contact for patients to 
report their treatment- related toxicity directly to their 
clinical team. In this article, we describe the use of the 
CTH in our oncology service in NHS Tayside, as well as 
the impact it has had on service provision in the wider 
local health service.
Our data demonstrate that the number of calls received 
by the CTH has increased by 83.6% over the last 5 years. 
This is in keeping with rising incidence of cancer8 as well 
Table 1 Total number of calls to the NHS Tayside Cancer Treatment Helpline between 2016 and 2020
Year 2016 2017 2018 2019 2020
Number of patients who received SACT 1212 1254 1285 1412 1399
Total number of calls 1137 1433 1773 1967 2087
Year on year increase (%) – +26.0 +23.7 +10.9 +6.1
Percentage year on year increase indicates the change from the previous year.
SACT, systemic anticancer therapy.
Table 2 Number of in- hours and out- of- hours calls from 
2016 to 2020
Year Total calls In hours Out of hours
2016 1137 530 (46.6%) 607 (53.4%)
2017 1433 777 (54.2%) 656 (45.8%)
2018 1773 1085 (61.2%) 688 (38.8%)
2019 1963 1235 (62.9%) 728 (37.1%)
2020 2053 1421 (69.2%) 632 (30.9%)
Percentage expressed as proportion of calls according to 
individual year.
Table 3 Median age (range) of patients who called the 
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as the availability of newer treatments such as immune 
checkpoint inhibitors, which provide the option of more 
lines of therapy for our patients. There was no significant 
change in the median age of patients we observed calling 
the CTH. Interestingly, while the in- hours calls increased 
(almost trebling), the out- of- hours calls did not, possibly 
reflecting a hesitancy from patients to phone outside 
traditional working hours. This is supported by the sharp 
increase in calls on a Monday, and in particular Monday 
morning, suggesting that patients were willing to wait to 
call until after the weekend.
Of the calls to the CTH, 35% were able to receive tele-
phone advice only. 85% were dealt with exclusively by the 
local oncology team either with telephone advice or in 
person review. This demonstrates the impact the CTH 
has had on appropriately directing patients and receiving 
early specialist care. This has also had a positive impact 
on other parts of the health service. As the CTH has 
developed and the team has increased in size and experi-
ence, the proportion of patients requiring review by their 
GP has fallen from 15% in 2016 to 11% in 2020, while 
the number receiving oncology review has increased by 
the same proportion. This demonstrates a shift in care 
model. This is also reflected in the triage classification 
which has demonstrated a reduction in acuity of calls and 
a move towards a greater proportion of green and single 
amber calls (data not included)—suggesting patients are 
phoning at an earlier stage of their toxicity burden. The 
reduction in the in hours admission rate over time adds 
weight to this theory and may also suggest an increasing 
confidence in the oncology clinical team in management 
of toxicity.
It is important to note that there was a change in triage 
outcome in 2020, which likely represents the impact of 
the COVID-19 pandemic on SACT delivery in Scotland.9 
During this year, a greater proportion of patients received 
advice only which may represent not only a propensity 
to avoid patients coming to a high- risk clinical area but 
also a tendency for clinicians at the beginning of the 
pandemic to dose de- escalate, use increased supportive 
measures and dose delay. All of these measures would 
reduce incidence and severity of toxicity.
Most tumour groups have observed an increase in call 
burden—reflecting the increase in number of patients 
with cancer and improved patient survival as well as the 
increased number of treatment options available. The 
Table 4 Breakdown of Cancer Treatment Helpline use by tumour group from 2017 to 2020
Tumour group 2017 2018 2019 2020 Total % change
Breast 295 (21%) 387 (22%) 477 (24%) 465 (22%) 1624 (22%) 58
Lung 305 (21%) 405 (23%) 413 (21%) 408 (20%) 1531 (21%) 38
Lower GI 167 (12%) 240 (14%) 264 (13%) 276 (13%) 947 (13%) 65
Gynae 191 (13%) 183 (10%) 220 (11%) 203 (10%) 797 (11%) 6
Upper GI 173 (12%) 155 (9%) 170 (9%) 263 (13%) 761 (10%) 52
Prostate 105 (7%) 101 (6%) 105 (5%) 80 (4%) 391 (5%) −24
Only tumour groups with more than 100 calls in 2017 are shown. The percentage (%) change from 2017 to 2020 is recorded.
GI, gastrointestinal.
Table 5 Outcome of calls to the Cancer Treatment Helpline between 2015 and 2020
Year Advice only (%) GP/NHS24 (%) Oncology review (%) ED review (%) Admission (%)
2016 30 15 26 3 27
2017 32 12 25 2 29
2018 31 10 30 2 27
2019 31 11 31 4 22
2020* 46 11 20 4 19
Values expressed as percentage of total calls to nearest whole number.
*COVID-19 pandemic.
ED, emergency department; GP, general practitioner.
Table 6 Outcome of Cancer Treatment Helpline call according to time of call; in hours and out of hours
Advice only GP/NHS24 Oncology review and discharge ED review Admission
In hours 1877 (37.0%) 700 (13.8%) 1523 (30.1%) 57 (1.1%) 911 (18.0%)
Out of hours 1042 (31.4%) 277 (8.4%) 691 (20.8%) 192 (5.8%) 1115 (33.6%)
Figures expressed as total number of calls and percentage.
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exception is prostate cancer, which has seen a reduc-
tion. This is likely a result of the introduction of the oral 
agents abiraterone and enzalutamide, which in general 
are better tolerated in comparison to chemotherapy and 
require regular clinical review in the clinic setting.
Likewise, all treatment types have noted an increase in 
calls. This increase is particularly marked for immune- 
checkpoint inhibitors which over the past 5 years have 
been licenced for use in several tumour groups both in 
the adjuvant and palliative setting.
The strengths of this report are that we have gener-
ated a large amount of data over a period of time from 
the same oncology unit. We have used a standardised 
reporting form which has enabled consistency in data 
recording and minimised missing data. Despite this, our 
report has several limitations. The first is that our centre is 
the smallest in Scotland and as such our patient numbers 
are lower than other centres. In addition, our model of 
care differs from the other Scottish cancer centres. This 
makes our findings challenging to extrapolate to larger 
centres both within Scotland and across the UK. We also 
must recognise that although standardised reporting 
forms were used, the recording of the patient symptoms 
using the UKONS tool is open to interuser variability and 
we did note some data were missing. Finally, there is a 
lack of granularity regarding burden of disease must also 
be acknowledged, as this could influence call burden and 
outcomes.
Overall, we feel our data support the use of a CTH within 
the NHS pathway for patients with cancer. It is accessible 
to patients of all ages and facilitates direct contact with 
the treating team. The end result is a more personalised 
and streamlined approach to toxicity management. 
Within our unit, use of the service continues to increase 
as delivery of SACT increases. In response, we are 
expanding our acute oncology team. This will have two 
main impacts; it will provide support for general medical 
teams caring for patients with cancer and it will enable 
expansion of ‘in hours’ times to cover from 08:00 to 20:00 
7 days per week. This may result in an increase in calls at 
weekends and subsequent fall in calls on Monday morn-
ings. Our data also suggest that admission rate may fall 
with an expansion of ‘in hours’ service. The decrease in 
proportional use of GP services and the high level (85%) 
of calls that were able to be managed solely by oncology 
services suggests this is a sustainable and beneficial model 
of care. Importantly, the fall in admission rates also 
suggests that patient outcomes are improving.
Although patient pathways in individual cancer centres 
differ across the UK, the principles detailed in this report 
are applicable in general—providing a direct route of 
contact for patients to receive advice and an appropriate 
management plan for their toxicity. This may involve 
various outcomes as shown in figure 1. Published data on 
the impact of such a model in other larger centres are 
currently lacking.
In summary, we provide an overview of the CTH in our 
region. We believe this is the first report of its kind. We 
have shown that use of the CTH has increased over the 
last 5 years and the ability to direct patients to specialist 
care early has removed pressure on other parts of the 
health system.
CONCLUSION
Early reporting and management of treatment- related 
toxicity improves patient’s outcomes and quality of life. 
The CTH provides a way for patients to report their symp-
toms directly to their clinical team and receive appro-
priate specialist advice at an early stage. We have demon-
strated that most of these calls can be managed solely by 
the oncology team and that this can remove the pressure 
on some of the other parts of the local health system. The 
CTH fits within our local AOS service.
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Table 7 Admission rate per 100 calls to the Cancer 
Treatment Helpline according to time of call; in hours or out 
of hours
Admission rate/100 calls
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